New immunotherapy for the treatment of malignant renal cell carcinoma
February 13, 2018 Source: Bio Valley
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];According to a recently published study, combined anti-angiogenic drugs and immunotherapeutic drugs can significantly inhibit tumorigenesis in patients with advanced renal cancer without negative effects. The study was conducted by researchers from the Georgetown Lombardi Comprehensive Cancer Research Center and the results were published in the latest issue of Lancet oncology.
In this study, the authors found that by combining axitinib and pembrolizumab, the above therapeutic effects can be achieved. Axitinib inhibits the formation of blood vessels in tumor tissues. Pembrolizumab is a class of immunological checkpoint inhibitors that block the defense mechanisms of cancer cells themselves, making them easily recognized by the body's immune system. Currently, the FDA has approved the use of the drug for the treatment of various types of cancer, including melanoma, lung cancer, bladder cancer, and head and neck cancer, but the treatment of this type of drug is still limited for patients with kidney cancer.
In this study, the authors enrolled 52 patients with advanced kidney cancer and had never received anticancer treatment before. First, the authors tested the dose tolerance of the drug in 11 of the patients, and then tested the effectiveness of the drug in all patients. First, the patient was treated with pembrolizumab by intravenous injection, followed by treatment every three weeks; at the same time, the patient received two treatments for axitinib twice daily. Finally, the researchers examined the volume of tumors in patients.
The results showed that 32% of patients receiving combination therapy had a significant tumor shrinkage, and the condition remained stable for more than 20 months. 88% of patients survived after 18 months of treatment.
Weighing Scale,Weighing Inidcator,Weighing Load Cell,Weighing Equipment,Electronic Scale,Weighing Controller
Changzhou Satidi Import and Export Co., Ltd. , https://www.czguanjiechuck.com